Grossberg R, Zhang Y, Gross R A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004 Oct;57(10):1107-10.
Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004 Jan;15(1):38-44.
Horne R, Cooper V, Gellaitry G, Date HL, Fisher M Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):334-41.
Krüsi A, Wood E, Montaner J, Kerr T Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010 Jan;21(1):4-9. doi: 10.1016/j.drugpo.2009.08.003. Epub 2009 Sep 10.
Lerner BH, Gulick RM, Dubler NN Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med. 1998 Oct 1;129(7):573-8. Review.
Lucas GM, Chaisson RE, Moore RD Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999 Jul 20;131(2):81-7.
Malta M, Magnanini MM, Strathdee SA, Bastos FI Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010 Aug;14(4):731-47. doi: 10.1007/s10461-008-9489-7. Epub 2008 Nov 20.
Møller T, Linaker OM Using brief self-reports and clinician scales to screen for substance use disorders in psychotic patients. Nord J Psychiatry. 2010 Apr;64(2):130-5. doi: 10.3109/08039480903274423.
Parsons JT, Golub SA, Rosof E, Holder C Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):443-50.
Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007 Oct 1;45(7):908-15. Epub 2007 Aug 20.
Radloff L The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Meas. 1977;1:385-401
Reynolds NR, Neidig JL Characteristics of nausea reported by HIV-infected patients initiating combination antiretroviral regimens. Clin Nurs Res. 2002 Feb;11(1):71-88.
Rüütel K, Pisarev H, Loit HM, Uusküla A Factors influencing quality of life of people living with HIV in Estonia: a cross-sectional survey. J Int AIDS Soc. 2009 Jul 16;12:13. doi: 10.1186/1758-2652-12-13.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804.
Sherer R Adherence and antiretroviral therapy in injection drug users. JAMA. 1998 Aug 12;280(6):567-8.
Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S23-35.
Stone VE Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001 Sep 15;33(6):865-72. Epub 2001 Aug 13. Review.
Torres-Madriz G, Lerner D, Ruthazer R, Rogers WH, Wilson IB Work-related barriers and facilitators to antiretroviral therapy adherence in persons living with HIV infection. AIDS Behav. 2011 Oct;15(7):1475-82. doi: 10.1007/s10461-010-9667-2.
WHO/UNAIDS/UNICEF Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007. http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf
Wolfe D Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy. 2007 Aug;18(4):246-54. Epub 2007 Mar 23.
HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.